Trial Profile
A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Ascending and Multiple-Ascending Doses of the Influenza A Virus Replication Inhibitor CC-42344
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs CC 42344 (Primary)
- Indications Influenza A virus H1N1 subtype; Influenza A virus infections
- Focus Adverse reactions; First in man
- Sponsors Cocrystal Pharma Inc
- 19 Mar 2024 Results published in the Cocrystal Pharma Inc Media Release.
- 29 May 2023 Number of arms changed from 7 to 9. Experimental: MAD cohort 2D and Experimental: MAD cohort 2E added to study protocol. Time frame changed from Day 1 to Day 21 to Day 1 to 7 days after last dose.
- 04 May 2023 According to a Cocrystal Pharma Inc media release, results from this trial were presented at the 7th Annual International Society for Influenza and Other Respiratory Virus Diseases (ISIRV) Antiviral Group Conference 2023.